dc.contributor.author | Castañeda, Santos | |
dc.contributor.author | Vicente-Rabaneda, Esther F. | |
dc.contributor.author | García-
Castañeda, Noelia | |
dc.contributor.author | Prieto-Peña, Diana | |
dc.contributor.author | Dessein, Patrick H. | |
dc.contributor.author | González-Gay Mantecón, Miguel Ángel | |
dc.contributor.other | Universidad de Cantabria | es_ES |
dc.date.accessioned | 2020-04-27T15:11:46Z | |
dc.date.available | 2021-01-01T03:45:14Z | |
dc.date.issued | 2020 | |
dc.identifier.issn | 1744-666X | |
dc.identifier.issn | 1744-8409 | |
dc.identifier.uri | http://hdl.handle.net/10902/18496 | |
dc.description.abstract | Introduction: Increased cardiovascular (CV) morbidity and mortality is observed in inflammatory joint diseases (IJDs) such as rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. However, the management of CV disease in these conditions is far from being well established.Areas covered: This review summarizes the main epidemiologic, pathophysiological, and clinical risk factors of CV disease associated with IJDs. Less common aspects on early diagnosis and risk stratification of the CV disease in these conditions are also discussed. In Europe, the most commonly used risk algorithm in patients with IJDs is the modified SCORE index based on the revised recommendations proposed by the EULAR task force in 2017.Expert opinion: Early identification of IJD patients at high risk of CV disease is essential. It should include the use of complementary noninvasive imaging techniques. A multidisciplinary approach aimed to improve heart-healthy habits, including strict control of classic CV risk factors is crucial. Adequate management of the underlying IJD is also of main importance since the reduction of disease activity decreases the risk of CV events. Non-steroidal anti-inflammatory drugs may have a lesser harmful effect in IJD than in the general population, due to their anti-inflammatory effects along with other potential beneficial effects. | es_ES |
dc.description.sponsorship | MA González-Gay’s research has been supported by grants from “Fondo de Investigaciones Sanitarias” PI06/0024, PS09/00748, PI12/00060, PI15/00525,PI18/00043, and RD12/0009/0013 and RD16/0012 (RIER) from “Instituto de Salud Carlos III” (ISCIII) (Spain), co-funded by FEDER funds. | es_ES |
dc.format.extent | 14 p. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Taylor & Francis | es_ES |
dc.rights | © Taylor & Francis. This is an Accepted Manuscript of an article published by Taylor & Francis in Expert Rev Clin Immunol on Epub 2019 Dec 10, available online: http://www.tandfonline.com/10.1080/1744666X.2019.1699058 | es_ES |
dc.source | Expert Rev Clin Immunol. 2020 Jan;16(1):23-36 | es_ES |
dc.subject.other | Ankylosing Spondylitis | es_ES |
dc.subject.other | Cardiovascular Disease | es_ES |
dc.subject.other | Cardiovascular Risk Factors | es_ES |
dc.subject.other | Inflammatory Joint Diseases | es_ES |
dc.subject.other | Prevention | es_ES |
dc.subject.other | Psoriatic Arthritis | es_ES |
dc.subject.other | Rheumatoid Arthritis | es_ES |
dc.title | Unmet needs in the management of cardiovascular risk in inflammatory joint diseases | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.relation.publisherVersion | https://doi.org/10.1080/1744666X.2019.1699058 | es_ES |
dc.rights.accessRights | openAccess | es_ES |
dc.identifier.DOI | 10.1080/1744666X.2019.1699058 | |
dc.type.version | acceptedVersion | es_ES |